Filicium.com

Drugs News

Data Analysts Captivated by Rs PowerWednesday, January 7, 2009 @ 6:14AMA programming languages versatility and its price (free) makes it a favorite of data analysts.

CNN Reporter Tops List for Surgeon GeneralWednesday, January 7, 2009 @ 6:13AMDr. Sanjay Gupta is a medical correspondent for the news network and a neurosurgeon.

Cequent To Present First Proof Of Activity Of An Oral RNAi Drug In Non-Human Primates At February Keystone ConferenceWednesday, January 7, 2009 @ 6:13AMCequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that the company has recently completed a successful toxicology study of its candidate CEQ501, an orally administered tkRNAi therapeutic targeting the primary oncogene (beta-catenin, CTNNB1) in FAP (familial adenomatous polyposis).

Chimerix Completes Phase I Study And Initiates A Phase II Multi-dose Clinical Trial For CMX001Wednesday, January 7, 2009 @ 6:13AMChimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that the Company has completed a single and multi-dose Phase I study of CMX001 in healthy volunteers. This study supports the further development of the drug for multiple dsDNA infections. The Company has initiated the first Phase II multi-dose clinical trial in patients.

Sequella Lead Drug Compound SQ109 Selected For Phase 1B Clinical Trial ProgramWednesday, January 7, 2009 @ 6:12AMSequella, Inc., a clinical-stage biopharmaceutical company focused on diseases of epidemic potential, announced today that SQ109, its lead drug candidate for the treatment of tuberculosis (TB), was the first drug approved for evaluation in a newly awarded clinical program contract to Dynport Vaccine Company LLC and Quintiles Transnational.